Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-004989
Filing Date
2025-11-14
Accepted
2025-11-14 16:03:32
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9133
  Complete submission text file 0000902664-25-004989.txt   11111
Mailing Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702
Business Address 200 CROSSING BOULEVARD FRAMINGHAM MA 01702 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88797 | Film No.: 251485671
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A